Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · President and CEO | November 27, 2018 | November 30, 2018 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 75,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 75,000 · Balance 75,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
GILEAD SCIENCES, INC.
Report date November 27, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,574,306 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Exercise / conversion · Acquired 280,000 · Balance 1,574,306 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Exercise / conversion · Disposed 280,000 · Balance 0 F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2016 Filed Aug 3, 2016 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $20.74 | $0.00 |
DisclosureSEC source: 0001127602-16-059418 · form4.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2017-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest over a five year period beginning 5/08/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 5/08/2012. Read SEC document |
| August 01, 2016 Filed Aug 3, 2016 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 70,000 | $70.94 | $4,965,590.00 |
DisclosureSEC source: 0001127602-16-059418 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 F3 · price: Sale prices reported for the transactions reported here range from $79.53 to $80.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 01, 2016 Filed Aug 3, 2016 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 70,000 | $20.74 | $1,451,800.00 |
DisclosureSEC source: 0001127602-16-059418 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 05, 2016 Filed Jul 7, 2016 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001127602-16-057737 · form4.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 05, 2016 Filed Jul 7, 2016 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,630 | $84.97 | $733,300.59 |
DisclosureSEC source: 0001127602-16-057737 · form4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 F4 · price: Sale prices reported for the transactions reported here range from $84.79 to $85.12. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 05, 2016 Filed Jul 7, 2016 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 103,370 | $84.28 | $8,711,620.46 |
DisclosureSEC source: 0001127602-16-057737 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,593 F3 · price: Sale prices reported for the transactions reported here range from $83.78 to $84.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 05, 2016 Filed Jul 7, 2016 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 112,000 | $16.40 | $1,836,240.00 |
DisclosureSEC source: 0001127602-16-057737 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 06, 2016 Filed Jun 8, 2016 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001127602-16-055086 · form4.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 06, 2016 Filed Jun 8, 2016 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 59,181 | $87.26 | $5,164,068.96 |
DisclosureSEC source: 0001127602-16-055086 · form4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 F4 · price: Sale prices reported for the transactions reported here range from $87.14 to $87.485. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 06, 2016 Filed Jun 8, 2016 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 52,819 | $86.57 | $4,572,709.85 |
DisclosureSEC source: 0001127602-16-055086 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118,144 F3 · price: Sale prices reported for the transactions reported here range from $86.13 to $87.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 06, 2016 Filed Jun 8, 2016 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 112,000 | $16.40 | $1,836,240.00 |
DisclosureSEC source: 0001127602-16-055086 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 02, 2016 Filed May 4, 2016 18:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001127602-16-051073 · form4.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,000 Underlying: Common Stock · 112,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 02, 2016 Filed May 4, 2016 18:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 57,329 | $88.14 | $5,052,788.87 |
DisclosureSEC source: 0001127602-16-051073 · form4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 F4 · price: Sale prices reported for the transactions reported here range from $87.765 to $88.74. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 02, 2016 Filed May 4, 2016 18:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 54,671 | $87.27 | $4,771,165.51 |
DisclosureSEC source: 0001127602-16-051073 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,292 F3 · price: Sale prices reported for the transactions reported here range from $86.76 to $87.76. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 02, 2016 Filed May 4, 2016 18:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 112,000 | $16.40 | $1,836,240.00 |
DisclosureSEC source: 0001127602-16-051073 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 04, 2016 Filed Apr 5, 2016 23:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001127602-16-048905 · form4.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,000 Underlying: Common Stock · 112,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| April 04, 2016 Filed Apr 5, 2016 23:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,836 | $94.88 | $1,502,443.67 |
DisclosureSEC source: 0001127602-16-048905 · form4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 F4 · price: Sale prices reported for the transactions reported here range from $94.805 to $94.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 04, 2016 Filed Apr 5, 2016 23:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 96,164 | $94.54 | $9,091,459.96 |
DisclosureSEC source: 0001127602-16-048905 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,799 F3 · price: Sale prices reported for the transactions reported here range from $93.80 to $94.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 04, 2016 Filed Apr 5, 2016 23:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 112,000 | $16.40 | $1,836,240.00 |
DisclosureSEC source: 0001127602-16-048905 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001127602-16-044742 · form4.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President, COO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,000 Underlying: Common Stock · 112,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 112,000 | $87.79 | $9,832,995.20 |
DisclosureSEC source: 0001127602-16-044742 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President, COO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 F3 · price: Sale prices reported for the transactions reported here range from $87.31 to $88.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 01, 2016 Filed Mar 3, 2016 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 112,000 | $16.40 | $1,836,240.00 |
DisclosureSEC source: 0001127602-16-044742 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President, COO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 45,433 | $91.15 | $4,141,217.95 |
DisclosureSEC source: 0001127602-16-042273 · form4.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director · President, COO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 58,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-042273 · form4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President, COO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104,396 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2013. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 16, 2016 Filed Feb 19, 2016 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 16,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-042273 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President, COO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,602 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of performance share awards made to the Reporting Person on February 1, 2014, and February 1, 2015. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2016, and committee certifications respectively. Read SEC document |
| February 15, 2016 Filed Feb 19, 2016 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 248 | $76.02 | $18,853.95 |
DisclosureSEC source: 0001127602-16-042273 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President, COO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,356 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 235,820 | $0.00 Strike: $84.05 | $0.00 |
DisclosureSEC source: 0001179110-16-018455 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,820 Underlying: Common Stock · 235,820 shares Expires 2026-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 07, 2015 Filed Dec 9, 2015 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-016040 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| December 07, 2015 Filed Dec 9, 2015 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 39,355 | $103.56 | $4,075,489.67 |
DisclosureSEC source: 0001179110-15-016040 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F4 · price: Sale prices reported for the transactions reported here range from $103.275 to $104.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 07, 2015 Filed Dec 9, 2015 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,645 | $102.93 | $6,242,487.01 |
DisclosureSEC source: 0001179110-15-016040 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,068,463 F3 · price: Sale prices reported for the transactions reported here range from $102.27 to $103.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 07, 2015 Filed Dec 9, 2015 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-016040 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2015 Filed Nov 12, 2015 18:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-014758 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 09, 2015 Filed Nov 12, 2015 18:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,509 | $108.27 | $921,266.88 |
DisclosureSEC source: 0001179110-15-014758 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F4 · price: Sale prices reported for the transactions reported here range from $108.13 to $108.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 09, 2015 Filed Nov 12, 2015 18:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 91,491 | $107.60 | $9,844,376.71 |
DisclosureSEC source: 0001179110-15-014758 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,617 F3 · price: Sale prices reported for the transactions reported here range from $107.11 to $108.11. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 09, 2015 Filed Nov 12, 2015 18:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-014758 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2015 Filed Oct 8, 2015 18:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-013939 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 07, 2015 Filed Oct 8, 2015 18:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 34,151 | $99.93 | $3,412,709.43 |
DisclosureSEC source: 0001179110-15-013939 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F5 · price: Sale prices reported for the transactions reported here range from $99.57 to $100.26. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 07, 2015 Filed Oct 8, 2015 18:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 50,799 | $99.08 | $5,033,368.12 |
DisclosureSEC source: 0001179110-15-013939 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,259 F4 · price: Sale prices reported for the transactions reported here range from $98.55 to $99.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 07, 2015 Filed Oct 8, 2015 18:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,050 | $98.04 | $1,475,446.32 |
DisclosureSEC source: 0001179110-15-013939 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114,058 F3 · price: Sale prices reported for the transactions reported here range from $97.52 to $98.49. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 07, 2015 Filed Oct 8, 2015 18:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-013939 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2015 Filed Sep 10, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-013190 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 08, 2015 Filed Sep 10, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $103.39 | $10,338,730.00 |
DisclosureSEC source: 0001179110-15-013190 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F3 · price: Sale prices reported for the transactions reported here range from $102.92 to $103.79. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 08, 2015 Filed Sep 10, 2015 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-013190 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2015 Filed Aug 11, 2015 20:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-011974 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 07, 2015 Filed Aug 11, 2015 20:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,100 | $115.28 | $357,363.04 |
DisclosureSEC source: 0001179110-15-011974 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F5 · price: Sale prices reported for the transactions reported here range from $115.23 to $115.30. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 07, 2015 Filed Aug 11, 2015 20:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 22,111 | $114.44 | $2,530,480.13 |
DisclosureSEC source: 0001179110-15-011974 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032,208 F4 · price: Sale prices reported for the transactions reported here range from $114.17 to $115.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 07, 2015 Filed Aug 11, 2015 20:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 74,789 | $113.73 | $8,506,104.48 |
DisclosureSEC source: 0001179110-15-011974 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054,319 F3 · price: Sale prices reported for the transactions reported here range from $113.15 to $114.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 07, 2015 Filed Aug 11, 2015 20:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $14.50 | $1,450,250.00 |
DisclosureSEC source: 0001179110-15-011974 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2015 Filed Jul 9, 2015 20:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-15-011071 · edgar.xml · derivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 100,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 07, 2015 Filed Jul 9, 2015 20:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $116.38 | $34,914.99 |
DisclosureSEC source: 0001179110-15-011071 · edgar.xml · nonDerivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,108 F6 · price: Sale prices reported for the transactions reported here range from $116.35 to $116.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.